Kadmon Holdings, Inc.
(NASDAQ : KDMN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.41%430.050.0%$6120.58m
BNTXBioNTech SE -3.62%359.180.0%$1251.77m
NVAXNovavax, Inc. 0.11%237.5479.4%$944.01m
SNSSSunesis Pharmaceuticals, Inc. 2.23%8.710.7%$608.86m
AMGNAmgen, Inc. 0.93%219.381.4%$559.38m
REGNRegeneron Pharmaceuticals, Inc. -0.20%651.882.7%$494.43m
GILDGilead Sciences, Inc. 0.39%71.611.0%$434.34m
ILMNIllumina, Inc. -0.65%447.013.5%$405.38m
TECHBio-Techne Corp. 0.92%534.354.5%$355.95m
BIIBBiogen, Inc. 0.17%300.191.7%$306.30m
VRTXVertex Pharmaceuticals, Inc. 0.64%188.301.9%$241.59m
ISEEIVERIC bio, Inc. 1.59%16.620.0%$194.78m
BGNEBeiGene Ltd. 4.65%403.141.3%$186.17m
LIFEaTyr Pharma, Inc. 0.49%10.313.2%$144.19m
EXASEXACT Sciences Corp. 5.22%108.1518.1%$135.69m

Company Profile

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.